Knight Therapeutics Inc., a leading Canadian specialty pharmaceutical company, announces that Health Canada has approved Probuphine (buprenorphine subdermal implant) for the management of opioid dependence […]
Mylan N.V. and Revance Therapeutics, Inc. announce a global collaboration and license agreement for the development and commercialization of a proposed biosimilar to BOTOX (onabotulinumtoxinA). BOTOX […]
Helix BioPharma will be presenting February 24, 2018, at the IASLC 18th Anual Targeted Therapies of Lung Cancer Meeting in Santa Monica. The Richmond Hill […]
MilliporeSigma introduces the Viresolve Barrier capsule filters to reduce the risk of bioreactor contamination. The filters are designed to remove viruses, mycoplasma and bacteria from cell culture media.
The GeneTitan Multi-Channel Instrument from Thermo Fisher Scientific offers streamlining array processing for discovery, exploration, and screening. The GeneTitan Instrument for expression applications and the […]
There are several viruses that can lead to oral or genital lesions and is internationally a problem on the rise. Viruses such as herpes simplex […]
Orfadin, an oral suspension which is meant to treat hereditary tyrosinemia type 1 (HT-1), has been approved by Health Canada.
A recent forecast expects the global insomnia therapeutics market to reach US$3.45 billion by 2025.
Vertex Pharmaceuticals Inc., the maker of the cystic fibrosis medication Orkambi want to negotiate with Canadian provinces a bulk deal for its drug. The provinces, […]
MilliporeSigma has launched Parteck M DPI for dry powder inhalation, a new grade of mannitol from MilliporeSigma that improves flow and releases characteristics of active pharmaceutical […]
Copyright © 2018 | WordPress Theme by MH Themes
